Výsledky vyhledávání - "Gabriel Okorogheye"

Akademický článek

Is single-inhaler triple therapy for COPD cost-effective in the UK? The IMPACT trial

Autor: Alan Martin, Dhvani Shah, Kerigo Ndirangu, Glenn A. Anley, Gabriel Okorogheye, Melanie Schroeder, Nancy Risebrough, Afisi S. Ismaila

Publikováno v: ERJ Open Research, Vol 8, Iss 1 (2022)

Background The IMPACT trial demonstrated superior outcomes following 52 weeks of once-daily single-inhaler treatment with fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) (100/62.5/25 μg) compared with once-daily FF/VI (100/25 μg) or UM

Externí odkaz: https://doaj.org/article/d24b893fc70949e9a4aed4830719690e

Zobrazit plný text záznamu

Akademický článek

Use of a flowable haemostat versus an oxidised regenerated cellulose agent in primary elective cardiac surgery: economic impact from a UK healthcare perspective

Autor: Mayur R. Joshi, Jacqueline Latham, Gabriel Okorogheye

Publikováno v: Journal of Cardiothoracic Surgery, Vol 12, Iss 1, Pp 1-8 (2017)

Abstract Background Flowable haemostatic agents have been shown to be superior to non-flowable agents in terms of haemostatic control and need for transfusion products in patients undergoing cardiac surgery. We investigated the economic impact of the

Externí odkaz: https://doaj.org/article/634e7e5866054a1690128861658cc957

Zobrazit plný text záznamu

Is single-inhaler triple therapy for COPD cost-effective in the UK? The IMPACT trial

Autor: Alan Martin, Dhvani Shah, Kerigo Ndirangu, Glenn A. Anley, Gabriel Okorogheye, Melanie Schroeder, Nancy Risebrough, Afisi S. Ismaila

Publikováno v: ERJ open research. 8(1)

BackgroundThe IMPACT trial demonstrated superior outcomes following 52 weeks of once-daily single-inhaler treatment with fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) (100/62.5/25 μg) compared with once-daily FF/VI (100/25 μg) or UME

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd93909778ca151b34a5a044cedeaaa9
https://pubmed.ncbi.nlm.nih.gov/35198630

Zobrazit plný text záznamu

Use of a flowable haemostat versus an oxidised regenerated cellulose agent in primary elective cardiac surgery: economic impact from a UK healthcare perspective

Autor: Gabriel Okorogheye, Jacqueline Latham, Mayur R. Joshi

Publikováno v: Journal of Cardiothoracic Surgery, Vol 12, Iss 1, Pp 1-8 (2017)
Journal of Cardiothoracic Surgery

Background Flowable haemostatic agents have been shown to be superior to non-flowable agents in terms of haemostatic control and need for transfusion products in patients undergoing cardiac surgery. We investigated the economic impact of the use of a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5fb5f7bc954181e45373c301cf9ba1b
http://link.springer.com/article/10.1186/s13019-017-0660-y

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání